Randomisation of Relapsed and Refractory High-Risk Neuroblastoma Patients Treated with Long-Term Infusion of Anti-GD2 Antibody Dinutuximab Beta with or Without Subcutaneous Interleukin-2, A SIOPEN Study
PEDIATRIC BLOOD & CANCER(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要